Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Yuya Seko,1 Taichiro Nishikawa,1 Atsushi Umemura,1 Kanji Yamaguchi,1 Michihisa Moriguchi,1 Kohichiroh Yasui,1 Mayumi Kimura,2 Hiroaki Iijima,3 Toshio Hashimoto,3 Yoshio Sumida,4 Takeshi Okanoue,5 Yoshito Itoh1 1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine,...

Full description

Saved in:
Bibliographic Details
Main Authors: Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y
Format: article
Language:EN
Published: Dove Medical Press 2018
Subjects:
canagliflozin
Japanese
NASH
fibrosis stages
SGLT2 inhibitor
type 2 diabetes mellitus
Specialties of internal medicine
RC581-951
Online Access:https://doaj.org/article/bfba1e10d95f4001b5ead934038fdfe6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/bfba1e10d95f4001b5ead934038fdfe6

Similar Items